DE60105785D1 - Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren - Google Patents

Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren

Info

Publication number
DE60105785D1
DE60105785D1 DE60105785T DE60105785T DE60105785D1 DE 60105785 D1 DE60105785 D1 DE 60105785D1 DE 60105785 T DE60105785 T DE 60105785T DE 60105785 T DE60105785 T DE 60105785T DE 60105785 D1 DE60105785 D1 DE 60105785D1
Authority
DE
Germany
Prior art keywords
estrogen receptor
receptor modulators
selective estrogen
halogened
triphenylethylene derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60105785T
Other languages
English (en)
Inventor
F Kaltenbach
L Trainor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of DE60105785D1 publication Critical patent/DE60105785D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
DE60105785T 2000-04-05 2001-04-05 Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren Expired - Lifetime DE60105785D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19457900P 2000-04-05 2000-04-05
PCT/US2001/011080 WO2001077057A2 (en) 2000-04-05 2001-04-05 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
DE60105785D1 true DE60105785D1 (de) 2004-10-28

Family

ID=22718125

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60105785T Expired - Lifetime DE60105785D1 (de) 2000-04-05 2001-04-05 Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren

Country Status (8)

Country Link
US (1) US6528681B2 (de)
EP (1) EP1268389B1 (de)
JP (1) JP2004517033A (de)
AT (1) ATE276995T1 (de)
AU (1) AU2001251330A1 (de)
CA (1) CA2403144A1 (de)
DE (1) DE60105785D1 (de)
WO (1) WO2001077057A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6180731A (ja) * 1984-09-28 1986-04-24 Toshiba Corp 管球の製造方法
CZ2004220A3 (cs) 2001-08-11 2004-06-16 Bristol-Myers Squibb Pharma Company Název neuveden
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
EP1692127B1 (de) * 2003-10-08 2008-07-02 Smithkline Beecham Corporation Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
US7196119B2 (en) * 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
WO2009149081A1 (en) * 2008-06-02 2009-12-10 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions
KR101698238B1 (ko) 2010-06-10 2017-01-19 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조정제 및 이의 용도
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
WO2013142266A1 (en) 2012-03-20 2013-09-26 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
JP2016517420A (ja) 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用
CA2971216A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
CA2301032C (en) 1997-08-15 2009-01-13 Duke University A method of preventing or treating estrogen-dependent diseases and disorders

Also Published As

Publication number Publication date
JP2004517033A (ja) 2004-06-10
WO2001077057A2 (en) 2001-10-18
US20020013297A1 (en) 2002-01-31
WO2001077057A3 (en) 2002-06-13
US6528681B2 (en) 2003-03-04
AU2001251330A1 (en) 2001-10-23
ATE276995T1 (de) 2004-10-15
EP1268389B1 (de) 2004-09-22
EP1268389A2 (de) 2003-01-02
CA2403144A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
WO2003016270A3 (en) Selective estrogen receptor modulators
DE60105785D1 (de) Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren
DK1353672T3 (da) Syntese af 4-amino-thalidomidenantiomerer
HK1045700A1 (en) Compositions an methods for cancer treatment by selectively inhibiting vegf
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
MXPA04003439A (es) Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
HK1052500A1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
IL139956A0 (en) Conformationally constrained backbone cyclized somatostatin analogs
PL2206719T3 (pl) Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
AU2003288644A1 (en) Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
WO2006065600A3 (en) N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
MX2007011280A (es) Dipirazoles como farmacos del sistema nervioso central.
WO2004089313A3 (en) Novel olanzapine forms and related methods of treatment
DE60206762D1 (de) Hexahydroazepino[4,5-g]indole und -indoline als 5-ht-rezeptor-liganden
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
GB0425548D0 (en) Radiolabelled ligands
DE60220179D1 (de) Substituierte benzopyrane als selektive agonisten am östrogenrezeptor-beta
TR200401601T4 (tr) Seçici estrojen reseptörü modülatörleri olarak trifeniletilen türevlerinin özel tuz biçimleri
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene

Legal Events

Date Code Title Description
8332 No legal effect for de